iTeos Therapeutics' (ITOS) "Buy" Rating Reiterated at HC Wainwright

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $46.00 price objective on the stock. HC Wainwright also issued estimates for iTeos Therapeutics' FY2029 earnings at $1.19 EPS.

Several other analysts also recently issued reports on the company. Wells Fargo & Company reduced their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating on the stock in a research report on Thursday, December 19th. Wedbush reissued an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday, March 5th.

iTeos Therapeutics Price Performance

Shares of ITOS stock traded down $0.10 during midday trading on Thursday, hitting $6.95. The company had a trading volume of 415,391 shares, compared to its average volume of 450,404. The stock has a market cap of $265.45 million, a price-to-earnings ratio of -2.21 and a beta of 1.38. iTeos Therapeutics has a 52-week low of $6.67 and a 52-week high of $18.75. The company's 50 day simple moving average is $7.52 and its 200 day simple moving average is $9.36.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.14) by $0.13. Analysts anticipate that iTeos Therapeutics will post -3.49 EPS for the current year.

Remove Ads

Institutional Trading of iTeos Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning grew its position in iTeos Therapeutics by 6.5% during the third quarter. Creative Planning now owns 19,636 shares of the company's stock valued at $200,000 after acquiring an additional 1,196 shares during the period. SG Americas Securities LLC lifted its holdings in shares of iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after acquiring an additional 1,508 shares in the last quarter. Wells Fargo & Company MN boosted its position in iTeos Therapeutics by 16.9% during the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock worth $128,000 after purchasing an additional 2,402 shares during the period. Point72 DIFC Ltd purchased a new stake in iTeos Therapeutics during the 3rd quarter worth $31,000. Finally, Virtus ETF Advisers LLC increased its holdings in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after purchasing an additional 3,293 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.